Tudriqev is an engineered herpes-virus therapy approved with nivolumab for certain advanced melanoma after anti-PD-1 treatment. Here is what the 24.2% response rate and accelerated approval do—and do not—show.
The FDA granted accelerated approval on August 6, 2026 to Tudriqev (vusolimogene oderparepvec, also called RP1) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that progressed after an anti-PD-1-based regimen.
Tudriqev is an engineered herpes simplex virus designed to infect and destroy tumor cells while helping stimulate an anti-tumor immune response. It is administered into tumors by trained oncology professionals; it is not related to consumer herpes treatments and cannot be used outside a cancer-care setting.
In the study supporting the approval, the combination produced an objective response rate of 24.2% in this difficult-to-treat population. Response rate describes the proportion of patients whose tumors shrink by a specified amount; it is not the same as cure rate, overall survival, or a guarantee for an individual patient.
Accelerated approval is an FDA pathway for serious conditions with unmet need. It may rely on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict benefit. In this case, continued approval is contingent on a confirmatory study verifying clinical benefit.
That caveat should be prominent in any discussion of the news. Tudriqev is an important option for a defined group of patients after progression on anti-PD-1 therapy, but the evidence base is still developing.
Sunscreen cannot treat melanoma or substitute for dermatology care. Consistent broad-spectrum sun protection is one evidence-informed way to reduce future UV exposure. We may earn a commission from the following link at no extra cost to you.
As an Amazon Associate, Stacking Years earns from qualifying purchases.
Apply generously before sun exposure and reapply as directed
A broad-spectrum daily sunscreen option for prevention-minded skin care. It does not treat melanoma, replace skin checks, or make prolonged sun exposure safe.
Rating: 4.6/5
View on Amazon · Affiliate link
Tudriqev plus nivolumab is a meaningful new option for a narrowly defined advanced-melanoma setting, with a 24.2% response rate in the supporting study. The accelerated-approval status means ongoing confirmatory evidence matters. Any treatment decision belongs with a medical oncology team.
The FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec-wtpg, formerly RP1) on August 6, 2026, for use with nivolumab in adults with unresectable advanced cutaneous melanoma that progressed after a PD-1-blocking regimen. This is a narrow oncology indication, not a prevention strategy or a treatment for every melanoma. The virus is genetically modified and injected into tumors; nivolumab is a separate immune-checkpoint medicine. Treatment selection, injection feasibility, and monitoring belong with an oncology team.
The approval followed the IGNYTE study, an open-label, single-arm trial. The FDA describes 140 enrolled adults, with 91 in the efficacy-evaluable group because they had at least one non-injected lesion. The approval was based on objective response rate and response duration, not a randomized comparison demonstrating longer overall survival. Accelerated approval can be contingent on confirmatory studies verifying clinical benefit. That distinction matters: a response signal can justify access in a serious setting while leaving uncertainty about comparative benefit.
Ask whether the person's cancer type, prior therapy, lesion locations, health status, and treatment goals match the approved indication. Discuss alternatives, expected treatment schedule, injection-related care, immune-related adverse effects from nivolumab, and how response will be measured. The clinician should review the current FDA approval information and prescribing information, including warnings and monitoring. Do not delay urgent oncology care to pursue an unproven supplement.
The evidence should be reassessed as confirmatory data and updated labeling become available. A news headline is not a personal treatment recommendation, and “accelerated approval” is not synonymous with a cure or a guarantee that every patient will respond. For the site's scoring approach and distinctions between evidence types, see our methodology, intervention rankings, and research library.
Is Tudriqev a vaccine? No. It is an oncolytic viral therapy used by intratumoral injection with nivolumab for the specific approved cancer setting.
Does approval prove improved survival? The FDA's accelerated approval was based on response measures; confirmatory evidence is still important.